{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:18:47Z","timestamp":1778498327533,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"DOI":"10.7759\/cureus.108640","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:47:38Z","timestamp":1778496458000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Low-Dose Versus Standard-Dose Immunotherapy in Advanced Solid Tumours: A Retrospective Real-World Study From a Resource-Constrained Setting"],"prefix":"10.7759","author":[{"given":"Ajay","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinesh","family":"Singhvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aadithya","family":"Lakshmi Narayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaib","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Shekhawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil VM","year":"2023","unstructured":"Patil VM, Noronha V, Menon N, et al.. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol. 2023, 41:222-32. 10.1200\/JCO.22.01015","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9012","article-title":"Checkpoint inhibitor accessibility in 15,000+ Indian patients","volume":"40","author":"Ravikrishna M","year":"2022","unstructured":"Ravikrishna M, Abraham G, Patil VM, et al.. Checkpoint inhibitor accessibility in 15,000+ Indian patients. J Clin Oncol. 2022, 40:9012. 10.1200\/JCO.2022.40.16_suppl.9012","journal-title":"J Clin Oncol"},{"key":"ref3","unstructured":"NCCN guidelines. (2026). https.\/\/www.nccn.org\/guidelines\/category_1."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi FS","year":"2018","unstructured":"Hodi FS, Ballinger M, Lyons B, et al.. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018, 36:850-8. 10.1200\/JCO.2017.75.1644","journal-title":"J Clin Oncol"},{"key":"ref5","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). (2017). https.\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5:649-55. 10.1097\/00000421-198212000-00014","journal-title":"Am J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030682","article-title":"Low-dose nivolumab with or without ipilimumab as adjuvant therapy following the resection of melanoma metastases: a sequential dual cohort Phase II clinical trial","volume":"14","author":"Schwarze JK","year":"2022","unstructured":"Schwarze JK, Garaud S, Jansen YJ, et al.. Low-dose nivolumab with or without ipilimumab as adjuvant therapy following the resection of melanoma metastases: a sequential dual cohort Phase II clinical trial. Cancers (Basel). 2022, 14:682. 10.3390\/cancers14030682","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian SL","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, et al.. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014, 32:1020-30. 10.1200\/JCO.2013.53.0105","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer RJ","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, et al.. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015, 33:1430-7. 10.1200\/JCO.2014.59.0703","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000512000","article-title":"Low-dose nivolumab in renal cell carcinoma: a real-world experience","volume":"99","author":"Zhao JJ","year":"2021","unstructured":"Zhao JJ, Kumarakulasinghe NB, Muthu V, et al.. Low-dose nivolumab in renal cell carcinoma: a real-world experience. Oncology. 2021, 99:192-202. 10.1159\/000512000","journal-title":"Oncology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden MS","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, et al.. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023, 389:1778-89. 10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomised, open-label, phase 3 study","volume":"23","author":"Burtness B","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, et al.. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomised, open-label, phase 3 study. Lancet. 2019, 23:1915-28. 10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000332","article-title":"Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity","volume":"3","author":"Yoo SH","year":"2018","unstructured":"Yoo SH, Keam B, Kim M, et al.. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open. 2018, 3:e000332. 10.1136\/esmoopen-2018-000332","journal-title":"ESMO Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2842","article-title":"Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer","volume":"23","author":"Feng Y","year":"2017","unstructured":"Feng Y, Wang X, Bajaj G, et al.. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res. 2017, 23:5394-405. 10.1158\/1078-0432.CCR-16-2842","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12140","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma","volume":"6","author":"Chatterjee MS","year":"2017","unstructured":"Chatterjee MS, Elassaiss-Schaap J, Lindauer A, et al.. Population pharmacokinetic\/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma. CPT Pharmacometrics Syst Pharmacol. 2017, 6:29-39. 10.1002\/psp4.12140","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19105999","article-title":"Modified-dose pembrolizumab and prognostic outcomes among non-small cell lung cancer patients: a chart review study","volume":"19","author":"To SY","year":"2022","unstructured":"To SY, Kao LT, Shih JH, et al.. Modified-dose pembrolizumab and prognostic outcomes among non-small cell lung cancer patients: a chart review study. Int J Environ Res Public Health. 2022, 19:5999. 10.3390\/ijerph19105999","journal-title":"Int J Environ Res Public Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33534","article-title":"Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer","volume":"149","author":"Low JL","year":"2021","unstructured":"Low JL, Huang Y, Sooi K, et al.. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. Int J Cancer. 2021, 149:169-76. 10.1002\/ijc.33534","journal-title":"Int J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.05.028","article-title":"Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small-cell lung cancer","volume":"22","author":"Sehgal K","year":"2021","unstructured":"Sehgal K, Bulumulle A, Brody H, et al.. Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small-cell lung cancer. Clin Lung Cancer. 2021, 22:e379-89. 10.1016\/j.cllc.2020.05.028","journal-title":"Clin Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo N","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D, et al.. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021, 385:1856-67. 10.1056\/NEJMoa2112435","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander RN","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, et al.. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023, 388:2159-70. 10.1056\/NEJMoa2302312","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0177-2","article-title":"Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy","volume":"4","author":"Agrawal S","year":"2016","unstructured":"Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016, 4:72. 10.1186\/s40425-016-0177-2","journal-title":"J Immunother Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.19.00142","article-title":"Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?","volume":"5","author":"Renner A","year":"2019","unstructured":"Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?. J Glob Oncol. 2019, 5:1-5. 10.1200\/JGO.19.00142","journal-title":"J Glob Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906251","article-title":"Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course","volume":"12","author":"Jiang M","year":"2022","unstructured":"Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol. 2022, 12:906251. 10.3389\/fonc.2022.906251","journal-title":"Front Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03954-8","article-title":"Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting","volume":"84","author":"Morrissey KM","year":"2019","unstructured":"Morrissey KM, Marchand M, Patel H, et al.. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019, 84:1257-67. 10.1007\/s00280-019-03954-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14369","article-title":"Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors","volume":"86","author":"Peer CJ","year":"2020","unstructured":"Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Br J Clin Pharmacol. 2020, 86:1769-77. 10.1111\/bcp.14369","journal-title":"Br J Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2203","article-title":"In silico re-optimization of atezolizumab dosing using population pharmacokinetic simulation and exposure-response simulation","volume":"63","author":"Peer CJ","year":"2023","unstructured":"Peer CJ, Schmidt KT, Arisa O, et al.. In silico re-optimization of atezolizumab dosing using population pharmacokinetic simulation and exposure-response simulation. J Clin Pharmacol. 2023, 63:672-80. 10.1002\/jcph.2203","journal-title":"J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2787","article-title":"Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource-constrained setting","volume":"38","author":"Chan TS","year":"2020","unstructured":"Chan TS, Hwang YY, Khong PL, Leung AY, Chim CS, Tse EW, Kwong YL. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource-constrained setting. Hematol Oncol. 2020, 38:726-36. 10.1002\/hon.2787","journal-title":"Hematol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15613","article-title":"Efficacy of a flat low dose of nivolumab in advanced cancer: a retrospective case series","volume":"42","author":"Joris S","year":"2022","unstructured":"Joris S, Fontaine C, Decoster L, Vanderauwera J, Thielemans K, Waelput W, DE-Gr\u00e8ve J. Efficacy of a flat low dose of nivolumab in advanced cancer: a retrospective case series. Anticancer Res. 2022, 42:1433-7. 10.21873\/anticanres.15613","journal-title":"Anticancer Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab\u00a0plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9 T","year":"2022","unstructured":"Andr\u00e9 T, Lonardi S, Wong KY, et al.. Nivolumab\u00a0plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022, 33:1052-60. 10.1016\/j.annonc.2022.06.008","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464084-efficacy-and-safety-of-low-dose-versus-standard-dose-immunotherapy-in-advanced-solid-tumours-a-retrospective-real-world-study-from-a-resource-constrained-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:47:40Z","timestamp":1778496460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464084-efficacy-and-safety-of-low-dose-versus-standard-dose-immunotherapy-in-advanced-solid-tumours-a-retrospective-real-world-study-from-a-resource-constrained-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.108640","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}